PR Newswire · Press release
VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte
Original release from PR Newswire
As distributed by PR Newswire, unedited.
Veracyte shares fell after its November 4, 2026 report despite $151.8 million in third-quarter revenue and a new $100 million buyback, as the market reacted to a weaker Decipher Prostate outlook. An investigation concerns potential securities law violations.
NEW YORK, Nov. 6, 2026 /PRNewswire/ -- A $100 million buyback authorization and $151.8 million in third-quarter revenue did not hold up Veracyte, Inc. (NASDAQ: VCYT) shares, which declined after the Company's November 4, 2026 report disclosed that Decipher Prostate volume was below its expectations. If you bought VCYT and are now holding losses, you are encouraged to submit your Veracyte loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.
In that report, the Company wrote: "Afirma outperformed, while Decipher Prostate volume was below our expectations." Full-year 2026 revenue guidance was narrowed to $590 million to $593 million, down from $590 million to $596 million. The new upper end sits below the cited analyst estimate of $593.894 million.
Reportedly, the Company now expects Decipher to increase by 12,000 to 15,000 tests and the 2027 outlook assumes lower-end growth. During the previous earnings call on July 30, 2026, CEO Marc Stapley claimed Decipher was progressing in a "highly predictable" pattern and was projected to average an increase of 20,000 tests per year.
SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of Veracyte investors.
Veracyte shareholders who lost money may request a free review of their VCYT losses or call (888) SueWallSt.
WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the VCYT Investigation
Q: How much did VCYT stock drop? A: Veracyte shares opened down approximately $23.25 per share, or roughly 44.27% to open at about $29.27 per share on November 5, 2026. The decline reportedly followed the Company's third-quarter report which disclosed that Decipher Prostate volume was below the Company's expectations and that guidance would be reduced in accord. Investors who purchased VCYT shares and suffered losses may be eligible to seek recovery.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Veracyte's statements about the growth outlook for its Decipher Prostate test were accurate and complete. The stock price declined after the Company disclosed on November 4, 2026 that Decipher Prostate volume was below its expectations.
Q: Who is eligible to participate in the VCYT investigation? A: Investors who purchased VCYT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do VCYT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my VCYT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought VCYT and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/vcyt-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-veracyte-302931637.html
SOURCE SueWallSt.com
